Sosei Group Corporation has entered into a multi-target partnership with Takeda to discover, develop and commercialize novel molecules, including small molecules and biologics, that modulate G protein-coupled receptor (GPCR) targets. The partnership will combine the proprietary GPCR-focused structure-based drug design capabilities at Sosei Heptares with Takeda’s extensive discovery, development and therapeutic area expertise directed towards multiple GPCR targets nominated by Takeda. The nomina...